Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies
Artikel i vetenskaplig tidskrift, 2014

Development of therapeutics for brain disorders is one of the more difficult challenges to be overcome by the scientific community due to the inability of most molecules to cross the blood-brain barrier (BBB). Antibody-conjugated nanoparticles are drug carriers that can be used to target encapsulated drugs to the brain endothelial cells and have proven to be very promising. They significantly improve the accumulation of the drug in pathological sites and decrease the undesirable side effect of drugs in healthy tissues. We review the systems that have demonstrated promising results in crossing the BBB through receptor-mediated endocytic mechanisms for the treatment of neurodegenerative disorders such as Alzheimer's and Parkinson's disease.

enable drug-delivery

transferrin-receptor

sterically stabilized liposomes

rat-brain

in-vivo

gene-therapy

central-nervous-system

amyloid-beta peptide

antitransferrin receptor antibody

alzheimers-disease

Författare

J. A. Loureiro

Universidade do Porto

Bárbara Gomes

Universidade do Porto

M. A. N. Coelho

Universidade do Porto

M. C. Pereira

Universidade do Porto

Sandra Rocha

Chalmers, Kemi- och bioteknik, Fysikalisk kemi

Nanomedicine

1743-5889 (ISSN) 1748-6963 (eISSN)

Vol. 9 5 709-722

Ämneskategorier

Biologiska vetenskaper

DOI

10.2217/NNM.14.27

Mer information

Senast uppdaterat

2018-03-19